SCHEMBL23924263

SCHEMBL23924263

O=C(Nc1cccc2cccnc12)[C@@H]1CN(C(=O)O)C[C@@H]1c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.50
HIF1A Q16665 1/20 0.49
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
MAPT P10636 2/20 0.49
TNKS O95271 4/20 0.48
TNKS2 Q9H2K2 2/20 0.48
POLB P06746 2/20 0.46
KDM4E B2RXH2 2/20 0.46
RECQL P46063 1/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
TDP1 Q9NUW8 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HTT P42858 2/20 0.45
HPGD P15428 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23923839 1.00 KDR (0.50) KDRHIF1AMEN1KMT2ASMN1; SMN2
SCHEMBL27209626 0.91 HIF1A (0.49) KDRHIF1AMEN1KMT2ASMN1; SMN2
SCHEMBL30089083 0.91 HIF1A (0.49) KDRHIF1AMEN1KMT2ASMN1; SMN2
SCHEMBL30089088 0.91 HIF1A (0.49) KDRHIF1AMEN1KMT2ASMN1; SMN2
SCHEMBL23951588 0.86 TACR1 (0.51) KDRHIF1AMEN1KMT2ASMN1; SMN2
SCHEMBL23951830 0.86 TACR1 (0.51) KDRHIF1AMEN1KMT2ASMN1; SMN2
SCHEMBL29900780 0.85 TNKS (0.49) KDRHIF1AMEN1KMT2ASMN1; SMN2
SCHEMBL29900723 0.85 TNKS (0.49) KDRHIF1AMEN1KMT2ASMN1; SMN2
SCHEMBL23924015 0.84 ALDH1A1 (0.48) MEN1KMT2ASMN1; SMN2MAPTKDM4E
SCHEMBL23924016 0.84 ALDH1A1 (0.48) MEN1KMT2ASMN1; SMN2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S.R.L. (IT) 2022-07-07 US disclosed
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S R L (IT) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 KDR 494/4885HIF1A 1847/4885MEN1 4081/4885
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 KDR 494/4885HIF1A 1847/4885MEN1 4081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.